chrisvoncsefalvay/vaers-outcomes huggingface dataset:
experienced pain with the first dose as well but not to this degree; Strong pain up to her shoulder and down to her fingers, pain is getting worse with time; This spontaneous case was reported by a consumer and describes the occurrence of PAIN (Strong pain up to her shoulder and down to her fingers, pain is getting worse with time) and VACCINATION SITE PAIN (experienced pain with the first dose as well but not to this degree) in a 72-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 048A21A) for COVID-19 vaccination.     No Medical History information was reported.   On 18-Mar-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 18-Mar-2021, the patient experienced PAIN (Strong pain up to her shoulder and down to her fingers, pain is getting worse with time). On an unknown date, the patient experienced VACCINATION SITE PAIN (experienced pain with the first dose as well but not to this degree). The patient was treated with IBUPROFEN (ADVIL [IBUPROFEN]) for Pain, at an unspecified dose and frequency. At the time of the report, PAIN (Strong pain up to her shoulder and down to her fingers, pain is getting worse with time) had not resolved and VACCINATION SITE PAIN (experienced pain with the first dose as well but not to this degree) outcome was unknown.            The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was not applicable. Concomitant medications reported were Blood pressure medications for drug use for unknown indication.
Mild fever, body aches, nausea, sore arm/red splotchiness/puffiness at injection site
This case was reported by a other health professional via call center representative and described the occurrence of fever in a female patient who received SHINGRIX for prophylaxis. On an unknown date, the patient received the 1st dose of SHINGRIX. On an unknown date, less than a year after receiving SHINGRIX, the patient experienced fever, muscle pain, chills, pain and bedridden. On an unknown date, the outcome of the fever, muscle pain, chills, pain and bedridden were unknown. It was unknown if the reporter considered the fever, muscle pain, chills, pain and bedridden to be related to SHINGRIX. Additional information was received as follows: The age at vaccination was not reported. The healthcare professional reported that the patient experienced fever, chills, pain, muscle ache, and she was in bed for over 24 hours after SHINGRIX.
Reported continuous Right Arm joint pain (shoulder, elbow, wrist) on the evening of 1/1/21.  Pain has not worsened or got any better as of 1/5/21.  Taking Motrin seems to help some with the pain.
Felt run down & tired; soreness in arm from the shot; This spontaneous case was reported by a consumer and describes the occurrence of FATIGUE (Felt run down & tired) and PAIN IN EXTREMITY (soreness in arm from the shot) in a 56-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 047B21A) for COVID-19 vaccination.     The patient's past medical history included Neck surgery (neck fusion).   On 18-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 15-Apr-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 18-Mar-2021, the patient experienced FATIGUE (Felt run down & tired) and PAIN IN EXTREMITY (soreness in arm from the shot). At the time of the report, FATIGUE (Felt run down & tired) and PAIN IN EXTREMITY (soreness in arm from the shot) outcome was unknown. Not Provided      For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.  This case was linked to MOD-2021-092640 (Patient Link).   Most recent FOLLOW-UP information incorporated above includes: On 06-May-2021: Updated additional contact information to previous case.
while in the process of diluting the Pfizer Biontech COVID19 vaccine (adult formulation), contents of the vaccine squirted in her eyes; experienced burning and redness; experienced burning and redness; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP) from medical information team for a Pfizer sponsored program (159558).  A female patient in her 40's received bnt162b2 (COMIRNATY), administration date 02Dec2021 (Lot number: EW0202, Expiration Date: 31Dec2021) as dose number unknown, single for covid-19 immunisation. The patient had no relevant medical history. There were no concomitant medications. The following information was reported: OCCUPATIONAL EXPOSURE TO PRODUCT (non-serious) with onset 02Dec2021, outcome "unknown", described as "while in the process of diluting the Pfizer Biontech COVID19 vaccine (adult formulation), contents of the vaccine squirted in her eyes"; OCULAR HYPERAEMIA (non-serious), EYE IRRITATION (non-serious) all with onset 02Dec2021, outcome "unknown" and all described as "experienced burning and redness". No follow-up attempts are possible. No further information is expected.
Patients have been administered doses while the temperature excursion assessment was ongoing (possible temperature excursion); Patients have been administered doses while the temperature excursion assessment was ongoing (possible temperature excursion); This spontaneous case was reported by an other health care professional and describes the occurrence of PRODUCT TEMPERATURE EXCURSION ISSUE (Patients have been administered doses while the temperature excursion assessment was ongoing (possible temperature excursion)) and POOR QUALITY PRODUCT ADMINISTERED (Patients have been administered doses while the temperature excursion assessment was ongoing (possible temperature excursion)) in a 26-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) .25 milliliter. On an unknown date, the patient experienced PRODUCT TEMPERATURE EXCURSION ISSUE (Patients have been administered doses while the temperature excursion assessment was ongoing (possible temperature excursion)) and POOR QUALITY PRODUCT ADMINISTERED (Patients have been administered doses while the temperature excursion assessment was ongoing (possible temperature excursion)). At the time of the report, PRODUCT TEMPERATURE EXCURSION ISSUE (Patients have been administered doses while the temperature excursion assessment was ongoing (possible temperature excursion)) and POOR QUALITY PRODUCT ADMINISTERED (Patients have been administered doses while the temperature excursion assessment was ongoing (possible temperature excursion)) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No concomitant medications were reported. No treatment medications were reported.  The reporter stated that their facility was not able to download the digital data logger, they had been put on hold by the state at the moment. They would need to treat this issue as a temperature excursion. There had been no power outages that would have impacted the Moderna vaccine. The data logger was unable to download for the months of Dec-2021, Jan-2022, and Feb-2022. The reporter did not have any questions and wanted to report this to Moderna.  The reporter stated that no adverse reactions were reported by any patients.
pt recv vax; fever of 103;pain inject site w/ redness on lt arm; tx w/ ice & motrin;
general fatigue for 12 hours; This spontaneous case was reported by a physician and describes the occurrence of FATIGUE (general fatigue for 12 hours) in a 72-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 062E21A and 004M10A) for COVID-19 vaccination.     Concurrent medical conditions included Immunocompromised.   On 25-Jan-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 20-Aug-2021, received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 25-Aug-2021,  after starting mRNA-1273 (Moderna COVID-19 Vaccine), the patient experienced FATIGUE (general fatigue for 12 hours). In August 2021, FATIGUE (general fatigue for 12 hours) had resolved.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No concomitant and treatment medication information was provided. In addition it was stated that the patient was having trouble receiving his booster (fourth dose) dose because the Pharmacies that the physician was going to have not heard of a 4th booster dose for Immunocompromised patients.   This case was linked to MOD-2022-474206 (Patient Link).
This spontaneous report was received from a medical assistant and refers to a patient of unknown age and gender. There was no information about patient's concomitant medications, concurrent conditions or pertinent medical history.  On 06-DEC-2021, the patient was vaccinated with a dose of hepatitis a vaccine, inactivated(VAQTA), lot number T017179 with expiration date 26-OCT-2021 (expired product administered), (dose, route and anatomical location were not reported) for prophylaxis. The of hepatitis a vaccine, inactivated(VAQTA) vaccine had no temperature excursion. No additional adverse events were reported.
Pt received Prevnar, Varivax, Hep b, and Hib on 04/15/2002. Parent reported on 04/18/2002 that the pt broke out in hives for 24 hrs. Parent is administering Benedryl. Area of hives reported to be on the back of torso and legs.
Information has been received from a registered nurse referring to a patient of unknown age and gender. The patient's pertinent medical history, drug reactions/allergies and concomitant mediations were not reported. On 15-JUL-2016, the patient was vaccinated with an expired dose of PNEUMOVAX 23 (lot# L001311 with expiration date 06-JUL-2016, once, subcutaneous or intramuscular), which had potency data for 6 months after expiration. No adverse effects were reported. No product quality complaint (PQC) involved. Additional information has been requested.
had the shots and it didn't save him; Initial information received on 13-Feb-2022 regarding an unsolicited valid Social Media serious case received from a consumer/non-hcp.  This case involves an unknown age and unknown gender patient, who had the shots and it didn't save him while receiving vaccine Influenza Vaccine.  The patient's past medical history, medical treatment(s), vaccination(s) and family history were not provided.   On an unknown date, the patient received a dose of suspect Influenza Vaccine produced by unknown manufacturer, lot number not reported via unknown route in unknown administration site for immunization.  It was reported by patients friend (reporter) that they lost a dear friend (patient) that had the shots and it didn't save him (death) (unknown latency) following the administration of Influenza Vaccine.   Action taken : not applicable.  Corrective treatment : No corrective treatment reported for the event.  Event outcome : At time of reporting, the outcome was Fatal for the event Death. It is unknown if an autopsy was done. The cause of death was reported as Death NOS.  Seriousness criteria : This event was assessed as medically significant and was leading to death. Final diagnosis was (fatal) for event Death.; Sender's Comments: Sanofi company comment dated 17-Feb-2022. This case involves an unknown age and unknown gender patient, who had the shots and it didn't save him while receiving vaccine Influenza Vaccine. The causal role of the company suspect vaccine cannot be assessed based on the temporal relevance. Further information regarding time to onset, concurrent condition during vaccination, previous vaccination, tolerance, allergic history, laboratory investigations excluding alternative etiologies for the reported event are needed to fully assess this case. Based upon the reported information, the role of the individual suspect vaccine cannot be assessed.; Reported Cause(s) of Death: lost a dear friend that had the shots and it didn't save him
This spontaneous report as received from a licensed practical nurse refers to a patient of unknown age and unknown gender. The patient pertinent medical history was not reported. On 22-OCT-2014, the patient was vaccinated with ZOSTAVAX (dose strength and route was not reported) (lot # K000456 and expiry date: 15-DEC-2014) which was improperly stored. Primary reporter was reporting excursion of 6 F since 01-JUN-2013 (confirmed date) affecting ZOSTAVAX, nurse also reported that products were not stored in an overall average support range of -58 degree F and 5 degree F. No adverse effects reported. No product quality complaint (PQC) was reported for ZOSTAVAX. This is one of the several reports from the same reporter. Additional information has been requested.
Information has been received from a physician concerning a 25 year old female with no known allergies who on 04-FEB-2007 was vaccinated with the first dose of Gardasil.  Concomitant therapy included hormonal contraceptives (unspecified).  On 04-FEB-2007 the patient broke out in hives after the first dose of Gardasil.  On 08-MAY-2007, the patient was vaccinated with the second dose of Gardasil.  Within one day, the patient broke out into hives after the second dose.  Medical attention was sought.  The physician treated the patient with Zyrtec and oral steroids.  As of 15-MAY-2007, the patient was recovering.  Additional information has been requested.
ACHES; This spontaneous report received from a consumer via a company representative concerned a male of unspecified age. The patient's height, and weight were not reported. The patient's past medical history included covid-19.The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin, and batch number were not reported) dose, start therapy date were not reported for prophylactic vaccination. The batch number was not reported. The Company is unable to perform follow-up to request batch/lot numbers. No concomitant medications were reported. On an unspecified date, the subject experienced aches. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The patient recovered from aches. This report was non-serious. This case, from the same reporter is linked to 20210627564.
Slight swelling at site 4x2 cm/ swelling now at 10x6/swelling at 14x10 cm, continued hot, itchy; Fever; Fatigue; Slight swelling at site 4x2 cm/ swelling now at 10x6/swelling at 14x10 cm, continued hot, itchy; Slight swelling at site 4x2 cm/ swelling now at 10x6/swelling at 14x10 cm, continued hot, itchy; Off label use; Interchange of vaccine products; Booster; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 56 year-old female patient (not pregnant) received bnt162b2 (BNT162B2), administered in arm right, administration date 06Aug2021 11:30 (Lot number: FC3180) at the age of 56 years as dose 3 (booster), single for covid-19 immunisation. Relevant medical history included: "Hormone replacement" (unspecified if ongoing). Concomitant medication(s) included: ESTROGEN taken for hormone replacement therapy; PROGESTERONE taken for hormone replacement therapy; BENADRYL. The following information was reported: OFF LABEL USE (non-serious) with onset 06Aug2021, outcome "recovering", described as "Off label use"; INTERCHANGE OF VACCINE PRODUCTS (non-serious) with onset 06Aug2021, outcome "recovering", described as "Interchange of vaccine products"; IMMUNISATION (non-serious) with onset 06Aug2021, outcome "recovering", described as "Booster"; PYREXIA (non-serious) with onset 07Aug2021 14:00, outcome "recovering", described as "Fever"; FATIGUE (non-serious) with onset 07Aug2021 14:00, outcome "recovering", described as "Fatigue"; VACCINATION SITE SWELLING (non-serious), VACCINATION SITE WARMTH (non-serious), VACCINATION SITE PRURITUS (non-serious) all with onset 07Aug2021 14:00, outcome "recovering" and all described as "Slight swelling at site 4x2 cm/ swelling now at 10x6/swelling at 14x10 cm, continued hot, itchy". The events "fever", "fatigue", "slight swelling at site 4x2 cm/ swelling now at 10x6/swelling at 14x10 cm, continued hot, itchy", "slight swelling at site 4x2 cm/ swelling now at 10x6/swelling at 14x10 cm, continued hot, itchy" and "slight swelling at site 4x2 cm/ swelling now at 10x6/swelling at 14x10 cm, continued hot, itchy" were evaluated at the emergency room visit. Therapeutic measures were taken as a result of pyrexia, fatigue, vaccination site swelling, vaccination site warmth, vaccination site pruritus.  Additional Information: Other medical history included given Novavax vaccine on 12Feb & 05Mar. Other medications in two weeks: Estrogen/progesterone Hormone replacement, Benadryl. Day 2-3: fever, fatigue, slight swelling at site 4x2 cm, Day 4: lower fever, resumed activities, swelling now at 10x6, Day 5: swelling at 14x10 cm, continued hot, itchy. Went to urgent treatment center. Given RX for amoxicillin 125 mg twice daily. Patient was not tested for covid prior to and post covid vaccine. No known allergies were reported.   No follow-up attempts are possible. No further information is expected.
L arm-vaccine given 10/30/02 has swelling, warmth and redness from fingers to vaccine site.
pt received her vaccine last week and today reports arm swollen, red, and itching right at injection site.  swelling is approx  3cm in diameter.   decided to report since it was 1 week ago that she received the vaccine and had not issues before today with arm swelling/redness
Hives; This spontaneous case from was received on 31-Jan-2023 from other non-healthcare professional (patient's parent) via Communications (reference number: SEQW23-00423) with additional information received on 01-Feb-2023 via Med Communications (being processed together) and concerned a male patient of unreported age.   The patient's medical history and concomitant medication were not reported.  On an unspecified date in Jan-2020, the patient was vaccinated with Flucelvax Quadrivalent vaccine (influenza vaccine inact sag 4v; dose: 0.5ml, route of administration: intramuscular, anatomical location: not reported), for prevention of influenza. The batch number was not reported.  On an unspecified date in Jan-2020, unspecified time after receiving Flucelvax Quadrivalen, the patient experienced hives. As reported, the patient only symptom was hives and he was treated with Benadryl (Acrivastine). According to the reporter's (parent's) understanding, their doctor at that time did report that he had a reaction.  On an unspecified date in 2020, after about six weeks, the patient recovered from the event.   On an unspecifired date, the parents and their son moved to another state and had a new doctor who was concerned about him having another reaction. The parents were trying to find out what was in the flu shot to see what the patient may have reacted to before he gets his next set of vaccines.  The reporter assessed the event of hives as related to Flucelvax Quadrivalent. As reported, the patient reacted with hives for about six weeks and his only symptom was hives.  The case was assessed as non-serious.  Company comment: The events of hives is assessed as possibly related to Flucelvax Quadrivalent due to plausible temporal relationship.; Reporter's Comments: As reported, the patient reacted with hives for about six weeks and his only symptom was hives.; Sender's Comments: The events of hives is assessed as possibly related to Flucelvax Quadrivalent due to plausible temporal relationship.
Patient presents on 12/08/2020 for a Wellness check up and one of the immunizations corresponding to the patient's age is DTaP ( KINRX ) with a lot # 53F43, administered on left thigh. At the time I was uploading the vaccine information in the system, I couldn't find the lot number, is when I realized, the immunization was expired and let Dr. know about the incident. The same day, Dr. called mother to let her know about the incident.
Sound on his head; This spontaneous case was reported by a consumer and describes the occurrence of TINNITUS (Sound on his head) in a 67-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     The patient's past medical history included No adverse event. Concomitant products included METFORMIN for an unknown indication.    On 11-Feb-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 18-Mar-2021, the patient experienced TINNITUS (Sound on his head). At the time of the report, TINNITUS (Sound on his head) outcome was unknown. Not Provided
Pt recv vax on 3/22/99; on 3/25/99 pt exp red/ blotchy rash on trunk & proximal extremities
During the  first night after the shot, I awoke with pain that radiated down the left side of my body from neck all the way down.  The pain felt muscular and joint...by morning it was all over my whole body.  So much joint pain.  I developed a huge bulge at the injection site...the size of my hand.  On the day following injection, we were heading out of town for the weekend.  The pain was pretty bad all over my body.  It got a little better each day...today 11/8, i still have a huge bulge on my arm...it is still painful to touch, just not as bad as it was.  Now the injection site itches really bad...but the bulge is still there.  Body aches are better so I?m hopeful that I?m on the upswing.  I?ve taken some ibuprofen...can?t really tell if it lessened the symptoms.
Information has been received from a pharmacist concerning an 18 year old female patient who on 28-FEB-2007 was vaccinated with a first dose of Gardasil, Lot #653735/0688F. Concomitant therapy included Menomune. The patient fainted 10 minutes after injection Gardasil. The patient fell and hit her head when she fainted. The patient then had a seizure for 30 seconds after she  fell after fainting. The patient was slow to wake and was Orthostatic (time line was unspecified). The patient also vomited twice (no time line). The patient recovered later in the day. The reporter considered the events to be disabling. Upon internal review, seizure was considered to be an other important medical event. Additional information has been requested.
cried unconsolably 5 hrs took to MD; t 100 ax; cont fussy til 7PM then slept til 7AM, sl redness on leg; no problems p/slept
9/30/15 Needle broke in right shoulder during flu vaccine at my physician's office. Right arm was sore immediately after. My right arm got progressively sore and increasingly limited in range of motion. During the next three months right arm had become extremely painful during movement and sleep. I was unable to reach up, behind me, or across my body. 12/30/15 Returned to primary care physician's office. PA prescribed Naproxen and physical therapy. 1/14/16 went to an orthopedic specialist. He ordered x-rays. Doctor diagnosed 'Adhesive Capsulitis' in my right shoulder. Prescribed a cortisone shot. 2/11/16 Follow up with orthopedic specialist. No improvement in range of motion and I was in constant pain. Received 2nd cortisone shot. 4/7/16 Orthopedic specialist decided to discontinue physical therapy and I was told the adhesive capsulitis will now just have to run its course. During the period of 1/7/16 to 4/1/16 I had 20 physical therapy sessions. To date, right arm still has not returned to full function and I still experience fairly constant pain daily, especially during the night.
After my second dose, I felt tingling in my fingers and numbness, along with headaches and vision issues. My booster was the third shot and the tingling was worse. Headaches got worse and vision remained the same (w/issues).
Eczema right away.  Flare-ups with colitis a few months later.
pt recvd vax & had been screaming for hrs & only took 1/2 oz of formula; pt was twitching; high pitched cry for 1 hr;